Cart
sales@molnova.com
BMS 753
CAS No. 215307-86-1
BMS 753( —— )
Catalog No. M33783 CAS No. 215307-86-1
BMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 55 | Get Quote |
|
| 10MG | 92 | Get Quote |
|
| 25MG | 205 | Get Quote |
|
| 50MG | 329 | Get Quote |
|
| 100MG | 447 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBMS 753
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS 753 is an agonist of isotype-selective retinoic acid receptor α (RARα, Ki= 2 nM).
-
DescriptionBMS 753 is an isotype-selective retinoic acid receptor α (RARα) agonist, with a Ki of 2 nM.
-
In VitroBMS 753 results in low levels of RARβ transcripts in WT cells, RARγ-/-, but not activates in RARa-/- cells.
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorRetinoid Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number215307-86-1
-
Formula Weight351.4
-
Molecular FormulaC21H21NO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (142.29 mM; Ultrasonic )
-
SMILESCC1(C)C(=O)C(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. M Géhin, et al. Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29.?
molnova catalog
related products
-
AM580
AM580 is a retinoic acid receptor agonist that is selective for RARα( IC50 : 8 nM ).
-
CD3254
CD3254 is a selective and potent retinoid X receptor-like (RXR) agonist that inhibits neuronal cell death with OGD/reoxygenation.
-
BMS493
BMS493 is an inverse agonist of the pan-retinoic acid receptor (RAR) that inhibits retinoic acid-induced differentiation, enhances the interaction of nuclear co-inhibitors with RARs, attenuates RA signaling, potentiates TPP-induced toxicity, and inhibits the increase in phospholipase A2 activity.
